Controversies in the oncosurgical management of liver limited stage IV colorectal cancer

Surgical Oncology

Volumn 23, Issue 2, 2014, Pages 53-60

  Jones, R P ^a,b   Stattner S ^c   Sutton, P ^a,b   Dunne, D F ^a,b   McWhirter, D ^a,b   Fenwick, S W ^b   Malik, H Z ^b   Poston, G J ^b  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

^c PARACELSUS MEDICAL UNIVERSITY   (Austria)

Author keywords

Colorectal; Liver; Oligometastases; Oncology; Surgery

Indexed keywords

BEVACIZUMAB; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; VATALANIB;

CANCER SURGERY; CHEMOSURGERY; CLINICAL DECISION MAKING; COLORECTAL CANCER; COLORECTAL LIVER METASTASIS; HUMAN; INDUCTION CHEMOTHERAPY; LIVER RESECTION; LONG TERM SURVIVAL; METASTATIC COLORECTAL CANCER; PRIORITY JOURNAL; REVIEW; TUMOR ABLATION; CANCER STAGING; COLORECTAL NEOPLASMS; EVIDENCE BASED MEDICINE; LIVER NEOPLASMS; PATHOLOGY; SECONDARY;

COLORECTAL NEOPLASMS; EVIDENCE-BASED MEDICINE; HUMANS; LIVER NEOPLASMS; NEOPLASM STAGING;

EID: 84901667314     PISSN: 09607404     EISSN: 18793320     Source Type: Journal    
DOI: 10.1016/j.suronc.2014.02.002     Document Type: Review

References (80)

1. P. Rougier, C. Milan, F. Lazorthes, G. Fourtanier, C. Partensky, and H. Baumel et al. Prospective study of prognostic factors in patients with unresected hepatic metastases from colorectal cancer. Fondation Française de Cancérologie Digestive Br J Surg 82 10 1995, Oct 1397 1400
2. R. Adam, E. Hoti, G. Folprecht, and A.B. Benson Accomplishments in 2008 in the management of curable metastatic colorectal cancer Gastrointest Cancer Res 3 5 Suppl. 2 2009, Sep S15 S22
3. J. Scheele, R. Stang, A. Altendorf-Hofmann, and M. Paul Resection of colorectal liver metastases World J Surg 19 1 1995 59 71
4. A. Taylor, J.N. Primrose, W. Langeberg, M.A. Kelsh, F. Mowat, and D. Alexander et al. Survival after liver resection in metastatic colorectal cancer: review and meta-analysis of prognostic factors Clin Epidemiol 2012, Nov 4283
5. E.J.A. Morris, D. Forman, J.D. Thomas, P. Quirke, E.F. Taylor, and L. Fairley et al. Surgical management and outcomes of colorectal cancer liver metastases Br J Surg 97 7 2010 1110 1118
6. D. Grünhagen, R.P. Jones, T. Treasure, C. Vasilakis, and G.J. Poston The history of adoption of hepatic resection for metastatic colorectal cancer: 1984-95 Crit Rev Oncol Hematol 86 3 2012, Nov 28 222 231
7. E. Vakiani, M. Janakiraman, R. Shen, R. Sinha, Z. Zeng, and J. Shia et al. Comparative genomic analysis of primary versus metastatic colorectal carcinomas J Clin Oncol 30 24 2012, Aug 20 2956 2962
8. S. Stremitzer, J. Stift, B. Gruenberger, D. Tamandl, T. Aschacher, and B. Wolf et al. KRAS status and outcome of liver resection after neoadjuvant chemotherapy including bevacizumab Br J Surg 99 11 2012, Nov 1575 1582
9. C. Pulitanò, F. Castillo, L. Aldrighetti, M. Bodingbauer, R.W. Parks, and G. Ferla et al. What defines 'cure' after liver resection for colorectal metastases? Results after 10 years of follow-up HPB (Oxford) 12 4 2010, May 244 249
10. G.K. Dy, T.J. Hobday, G. Nelson, H.E. Windschitl, M.J. O'Connell, and S.R. Alberts et al. Long-term survivors of metastatic colorectal cancer treated with systemic chemotherapy alone: a North Central Cancer Treatment Group review of 3811 patients, N0144 Clin Colorectal Cancer 8 2 2009, Apr 88 93
11. R. Adam, A. Frilling, D. Elias, C. Laurent, E. Ramos, and L. Capussotti et al. Liver resection of colorectal metastases in elderly patients Br J Surg 97 3 2010, Mar 366 376
12. E. Van Cutsem, B. Nordlinger, R. Adam, C.H. Köhne, C. Pozzo, and G. Poston et al. Towards a pan-European consensus on the treatment of patients with colorectal liver metastases Eur J Cancer 42 14 2006, Sep 2212 2221 (Pubitemid 44307626)
13. R. Adam, A. De Gramont, J. Figueras, A. Guthrie, N. Kokudo, and F. Kunstlinger et al. The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus Oncologist 17 10 2012 1225 1239
14. R.P. Jones, R. Jackson, D.F. Dunne, H.Z. Malik, S.W. Fenwick, and G.J. Poston et al. Systematic review and meta-analysis of follow-up after hepatectomy for colorectal liver metastases Br J Surg 99 4 2012, Jan 19 477 486
15. R.R. Weichselbaum, and S. Hellman Oligometastases revisited Nat Rev Clin Oncol 8 6 2011, Jun 378 382
16. G.P. Gupta, and J. Massagué Cancer metastasis: building a framework Cell 127 4 2006, Nov 17 679 695 (Pubitemid 44781029)
17. S. Yachida, S. Jones, I. Bozic, T. Antal, R. Leary, and B. Fu et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer Nature 467 7319 2010, Oct 28 1114 1117
18. E. Van Cutsem, C.H. Köhne, E. Hitre, J. Zaluski, C.R. Chang Chien, and A. Makhson et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer N Engl J Med 360 14 2009, Apr 2 1408 1417
19. C. Kohne Efficacy of chemotherapy + cetuximab according to metastatic site in KRAS wild type metastatic colorectal cancer: analysis of CRYSTAL and OPUS studies Ann Oncol 22 Suppl. 5 2011, Jun 1 O-0002
20. J. Tabernero Results from VELOUR, a phase III study of Aflibercept versus placebo in combination with FOLFIRI for the treatment of patients with previously treated metastatic colorectal cancer In: European Multidisciplinary Cancer Congress, 2011, Sep 1 Eur Journ Cancer 47 Suppl. 2 2011 5
21. L. Viganò, L. Capussotti, E. Barroso, G. Nuzzo, C. Laurent, and J.N.M. Ijzermans et al. Progression while receiving preoperative chemotherapy should not be an absolute contraindication to liver resection for colorectal metastases Ann Surg Oncol 19 9 2012, May 5 2786 2796
22. Y.A. Lussier, H.R. Xing, J.K. Salama, N.N. Khodarev, Y. Huang, and Q. Zhang et al. MicroRNA expression characterizes oligometastasis(es) PLoS One 6 12 2011 e28650
23. S.C. Bruin, J.J. de Ronde, B. Wiering, L.M. Braaf, J.H.W. de Wilt, and A.D. Vincent et al. Selection of patients for hepatic surgery of colorectal cancer liver metastasis based on genomic aberrations Ann Surg Oncol 20 Suppl. 3 2013, Dec S560 S569
24. H. Kuramochi, K. Hayashi, K. Uchida, S. Miyakura, D. Shimizu, and D. Vallböhmer et al. Vascular endothelial growth factor messenger RNA expression level is preserved in liver metastases compared with corresponding primary colorectal cancer Clin Cancer Res 12 1 2006, Jan 1 29 33 (Pubitemid 43166172)
25. H. Kobayashi, K. Sugihara, H. Uetake, T. Higuchi, M. Yasuno, and M. Enomoto et al. Messenger RNA expression of vascular endothelial growth factor and its receptors in primary colorectal cancer and corresponding liver metastasis Ann Surg Oncol 15 4 2008, Apr 1232 1238
26. S.E. Baldus, K.L. Schaefer, R. Engers, D. Hartleb, N.H. Stoecklein, and H.E. Gabbert Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases Clin Cancer Res 16 3 2010, Feb 1 790 799
27. A. Italiano, I. Hostein, I. Soubeyran, T. Fabas, D. Benchimol, and S. Evrard et al. KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications Ann Surg Oncol 17 5 2010, May 1429 1434
28. O.M. Jones, M. Rees, T.G. John, S. Bygrave, and G. Plant Biopsy of resectable colorectal liver metastases causes tumour dissemination and adversely affects survival after liver resection Br J Surg 92 9 2005, Sep 1165 1168 (Pubitemid 41284884)
29. M. Gerlinger, A.J. Rowan, S. Horswell, J. Larkin, D. Endesfelder, and E. Gronroos et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing N Engl J Med 366 10 2012, Mar 8 883 892
30. R.P. Jones, J.N. Vauthey, R. Adam, M. Rees, D. Berry, and R. Jackson et al. Effect of specialist decision-making on treatment strategies for colorectal liver metastases Br J Surg 99 9 2012, Sep 1263 1269
31. H. Bismuth, R. Adam, F. Lévi, C. Farabos, F. Waechter, and D. Castaing et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy Ann Surg 224 4 1996, Oct 509 520 discussion 520-2
32. V.W. Lam, C. Spiro, J.M. Laurence, E. Johnston, M.J. Hollands, and H.C. Pleass et al. A systematic review of clinical response and survival outcomes of downsizing systemic chemotherapy and rescue liver surgery in patients with initially unresectable colorectal liver metastases Ann Surg Oncol 19 4 2012, Apr 1292 1301
33. G. Folprecht, A. Grothey, S. Alberts, H.R. Raab, and C.H. Köhne Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates Ann Oncol 16 8 2005, Aug 1311 1319 (Pubitemid 41158476)
34. NICE Colorectal cancer quality standard 2012, Aug
35. A. Falcone, S. Ricci, I. Brunetti, E. Pfanner, G. Allegrini, and C. Barbara et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest J Clin Oncol 25 13 2007, May 1 1670 1676 (Pubitemid 46797946)
36. W.D. Roock, B. Claes, D. Bernasconi, J.D. Schutter, B. Biesmans, and G. Fountzilas et al. Effects of KRAS, BRAF, NRAS, and PIK3CAmutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis Lancet Oncol 11 8 2010 753 762
37. S. Tejpar, I. Celik, M. Schlichting, U. Sartorius, C. Bokemeyer, and E. Van Cutsem Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab J Clin Oncol 30 29 2012 3570 3577
38. J. Folkman Tumor angiogenesis: therapeutic implications N Engl J Med 285 21 1971, Nov 18 1182 1186
39. L.M. Ellis Mechanisms of action of bevacizumab as a component of therapy for metastatic colorectal cancer Semin Oncol 33 5 Suppl. 10 2006, Oct S1 S7
40. C. Bokemeyer, I. Bondarenko, A. Makhson, J.T. Hartmann, J. Aparicio, and F. de Braud et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer J Clin Oncol 27 5 2009, Feb 10 663 671
41. E. Van Cutsem, C.H. Köhne, I. Láng, G. Folprecht, M.P. Nowacki, and S. Cascinu et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status J Clin Oncol 29 15 2011, May 20 2011 2019
42. G. Folprecht, T. Gruenberger, W.O. Bechstein, H.R. Raab, F. Lordick, and J.T. Hartmann et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial Lancet Oncol 11 1 2010, Jan 38 47
43. L.-C. Ye, T.-S. Liu, L. Ren, Y. Wei, D.-X. Zhu, and S.-Y. Zai et al. Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases J Clin Oncol 31 16 2013, Jun 1 1931 1938
44. G. Masi, F. Loupakis, L. Salvatore, L. Fornaro, C. Cremolini, and S. Cupini et al. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial Lancet Oncol 11 9 2010, Sep 845 852
45. F. Loupakis FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev as first-line treatment of metastatic colorectal cancer (MCRC): results of the phase III randomized TRIBE trial J Clin Oncol 30 Suppl. 34 2013, Feb 1 Abst 366
46. S. Schwartzberg PEAK (study 20070509): a randomized phase II study of mFOLFOX6 with either panitumumab or bevacizumab as first-line treatment in patients with unresectable wildtype KRAS metastatic colorectal cancer J Clin Oncol 30 Suppl. 34 2013, Feb 1 Abstr 446
47. A.P. Guglielmi, and A.F. Sobrero Second-line therapy for advanced colorectal cancer Gastrointest Cancer Res 1 2 2007, Mar 57 63
48. D. Cunningham, Y. Humblet, S. Siena, D. Khayat, H. Bleiberg, and A. Santoro et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N Engl J Med 351 4 2004, Jul 22 337 345 (Pubitemid 38944402)
49. C. Tournigand, T. André, E. Achille, G. Lledo, M. Flesh, and D. Mery-Mignard et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study J Clin Oncol 22 2 2004, Jan 15 229 237 (Pubitemid 41095086)
50. G.P. Kim, D.J. Sargent, M.R. Mahoney, K.M. Rowland, P.A. Philip, and E. Mitchell et al. Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841 J Clin Oncol 27 17 2009, Jun 10 2848 2854
51. M.T. Seymour, T.S. Maughan, J.A. Ledermann, C. Topham, R. James, and S.J. Gwyther et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial Lancet 370 9582 2007, Jul 14 143 152 (Pubitemid 47042894)
52. M. Koopman, N.F. Antonini, J. Douma, J. Wals, A.H. Honkoop, and F.L. Erdkamp et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial Lancet 370 9582 2007, Jul 14 135 142 (Pubitemid 47042893)
53. A. Brouquet, M.J. Overman, S. Kopetz, D.M. Maru, E.M. Loyer, and A. Andreou et al. Is resection of colorectal liver metastases after a second-line chemotherapy regimen justified? Cancer 117 19 2011, Oct 1 4484 4492
54. D.G. Blazer, Y. Kishi, D.M. Maru, S. Kopetz, Y.S. Chun, and M.J. Overman et al. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases J Clin Oncol 26 33 2008, Nov 20 5344 5351
55. J.N. Vauthey, T.M. Pawlik, D. Ribero, T.T. Wu, D. Zorzi, and P.M. Hoff et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases J Clin Oncol 24 13 2006, May 1 2065 2072 (Pubitemid 46622116)
56. B. Giantonio High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (ECOG) 3200 Proc Am Soc Clin Oncol 23 16s 2005, Jan 1 Abstract 2
57. C. Kohne Results of an interim analysis of a multinational randomized, double-blind, phase III study in patients (pts) with previously treated metastatic colorectal cancer (mCRC) receiving FOLFOX and PTK787/ZK 222584 (PTK/ZK) or placebo (CONFIRM2) Proc Am Soc Clin Oncol 23 15s 2006, Jan 1 Abstr 3508
58. E. Van Cutsem, J. Tabernero, R. Lakomy, H. Prenen, J. Prausová, and T. Macarulla et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen J Clin Oncol 30 28 2012, Oct 1 3499 3506
59. A. Hendlisz, M. Van den Eynde, M. Peeters, G. Maleux, B. Lambert, and J. Vannoote et al. Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy J Clin Oncol 28 23 2010, Aug 10 3687 3694
60. NCCN NCCN clinical practice guidelines in oncology Colon Cancer 2012 6 80 v. 3.2012. colon.pdf Jan 1;[cited 2012, Aug 18]
61. J. Poston, D. Tait, S. O'Connell, A. Bennett, S. Berendse On behalf of the Guideline Development Group Diagnosis and management of colorectal cancer: summary of NICE guidance BMJ 343 2011, Nov 9 d6751 (nov09 2)
62. G. Portier, D. Elias, O. Bouche, P. Rougier, J.F. Bosset, and J. Saric et al. Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial J Clin Oncol 24 31 2006, Nov 1 4976 4982 (Pubitemid 46631399)
63. E. Mitry, A.L. Fields, H. Bleiberg, R. Labianca, G. Portier, and D. Tu et al. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials J Clin Oncol 26 30 2008, Oct 20 4906 4911
64. M. Ychou, W. Hohenberger, S. Thezenas, M. Navarro, J. Maurel, and C. Bokemeyer et al. A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer Ann Oncol 20 12 2009, Dec 1964 1970
65. A. Wein, C. Riedel, W. Brückl, S. Merkel, R. Ott, and B. Hanke et al. Neoadjuvant treatment with weekly high-dose 5-Fluorouracil as 24-hour infusion, folinic acid and oxaliplatin in patients with primary resectable liver metastases of colorectal cancer Oncology 64 2 2003 131 138 (Pubitemid 36173378)
66. R. Adam, P. Bhangui, G. Poston, D. Mirza, G. Nuzzo, and E. Barroso et al. Is perioperative chemotherapy useful for solitary, metachronous, colorectal liver metastases? Ann Surg 252 5 2010, Nov 774 787
67. B. Nordlinger, H. Sorbye, B. Glimelius, G.J. Poston, P.M. Schlag, and P. Rougier et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial Lancet 371 9617 2008, Mar 22 1007 1016 (Pubitemid 351392040)
68. B. Nordlinger, E. Van Cutsem, T. Gruenberger, B. Glimelius, G. Poston, and P. Rougier et al. Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel Ann Oncol 20 6 2009, Jun 985 992
69. B. Nordlinger, J.N. Vauthey, G. Poston, S. Benoist, P. Rougier, and E. Van Cutsem The timing of chemotherapy and surgery for the treatment of colorectal liver metastases Clin Colorectal Cancer 9 4 2010, Oct 212 218
70. B. Nordlinger, H. Sorbye, B. Glimelius, G.J. Poston, P.M. Schlag, and P. Rougier et al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial Lancet Oncol 14 12 2013, Nov 1208 1215
71. R. Adam, R.J. de Haas, D.A. Wicherts, E. Vibert, C. Salloum, and D. Azoulay et al. Concomitant extrahepatic disease in patients with colorectal liver metastases: when is there a place for surgery? Ann Surg 253 2 2011, Feb 349 359
72. M.C. de Jong, S.C. Mayo, C. Pulitano, S. Lanella, D. Ribero, and J. Strub et al. Repeat curative intent liver surgery is safe and effective for recurrent colorectal liver metastasis: results from an international multi-institutional analysis J Gastrointest Surg 13 12 2009, Dec 2141 2151
73. T. Ruers, C. Punt, F. Van Coevorden, J.P. Pierie, I. Borel-Rinkes, and J.A. Ledermann et al. Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004) Ann Oncol 23 10 2012, Mar 19 2619 2626
74. R. Sauer, H. Becker, W. Hohenberger, C. Rödel, C. Wittekind, and R. Fietkau et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer N Engl J Med 351 17 2004, Oct 21 1731 1740
75. G. Mentha, P.E. Majno, A. Andres, L. Rubbia-Brandt, P. Morel, and A.D. Roth Neoadjuvant chemotherapy and resection of advanced synchronous liver metastases before treatment of the colorectal primary Br J Surg 93 7 2006, Jul 872 878 (Pubitemid 44035261)
76. D.A. Wicherts, R. Miller, R.J. de Haas, G. Bitsakou, E. Vibert, and L.A. Veilhan et al. Long-term results of two-stage hepatectomy for irresectable colorectal cancer liver metastases Ann Surg 248 6 2008, Dec 994 1005
77. M. Narita, E. Oussoultzoglou, D. Jaeck, P. Fuchschuber, E. Rosso, and P. Pessaux et al. Two-stage hepatectomy for multiple bilobar colorectal liver metastases Br J Surg 98 10 2011, Oct 1463 1475
78. S.L. Wong, P.B. Mangu, M.A. Choti, T.S. Crocenzi, G.D. Dodd, and G.S. Dorfman et al. American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer J Clin Oncol 28 3 2010, Jan 20 493 508
79. E.K. Abdalla, J.N. Vauthey, L.M. Ellis, V. Ellis, R. Pollock, and K.R. Broglio et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases Ann Surg 239 6 2004, Jun 818 825 discussion 825-7
80. S. Evrard, M. Rivoire, -P. Arnaud, E. Lermite, C. Bellera, and M. Fonck et al. Unresectable colorectal cancer liver metastases treated by intraoperative radiofrequency ablation with or without resection Br J Surg 99 4 2012, Apr 558 565